Charming Medical Limited Class A Ordinary Shares
NASDAQ:MCTAMedical - Care Facilities
+$0.00 today
- Market cap
- $445.55M
- Beta
- 0.00
- P/E (TTM)
- 414.6
- EPS (TTM)
- $0.07
Volume 0.00M
Average 0.87M
MCTA Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
Charming Medical Limited Class A Ordinary SharesNASDAQ: MCTA
Financing Cash Flow · FY2024 · year ended Mar 2025
Financing cash flow grows 420.5% year over year
FY2024 financing cash flow of $521.3K rose 420.5% year over year.
Context
- Financing cash flow amounted to 8.4% of revenue in FY2024, up 6.7 pp from a year earlier.
- Financing cash flow increased in 2 of the last 2 fiscal years.
- FY2024 was the highest annual figure in the 3 fiscal years shown.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2024
- 521.3K USD
- Year-over-year change
- +420.5%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2024 | 2025-03-31 | 521.3K | +420.5% |
| FY2023 | 2024-03-31 | 100.15K | +107.0% |
| FY2022 | 2023-03-31 | (1.43M) | — |
Financing Cash Flow vs competitors
How MCTA compares with its peers on the latest reported figures
- MCTA's FY2024 financing cash flow of $521.3K is the smallest of the 10 companies compared; the peer median is $2.26M.
- Its year-over-year change of +420.5% is the 2nd highest of 10, against a peer median of +110.3%.
- Financing cash flow amounts to 8.4% of revenue for MCTA, versus a peer median of 2.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $723.38M | +13967.7% | +995.9% | 18455.2% | |
| LTM Mar 2026 | $141.69M | +10.0% | -4.0% | — | |
| LTM Mar 2026 | $41.49M | +179.7% | +74.7% | 12.1% | |
| LTM Mar 2026 | $16.27M | +323.0% | -50.0% | 3.0% | |
| LTM Mar 2026 | $14.74M | -59.0% | -47.0% | 1.5% | |
| LTM Mar 2026 | $9.41M | -75.6% | +14.1% | 10.4% | |
| LTM Mar 2026 | $7.98M | +141.6% | — | 0.1% | |
| LTM Mar 2026 | $2.26M | -98.0% | -33.5% | 1.8% | |
| LTM Feb 2026 | $590K | +110.3% | -46.8% | 0.7% | |
MCTACharming Medical Limited Class A Ordinary Shares | FY2024 | $521.3K | +420.5% | — | 8.4% |
| Peer median (excluding MCTA) | $2.26M | +110.3% | -18.7% | 2.4% | |
Competitors are the stored peer set for MCTA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2022 Mar 2023 | FY2023 Mar 2024 | FY2024 Mar 2025 |
|---|---|---|---|
| Net Income | (335.61K) | 821.74K | 1.2M |
| Depreciation & Amortization | 211.08K | 391.7K | 263.45K |
| Deferred Income Tax | 0 | 62.48K | 134.87K |
| Stock-Based Compensation | 0 | 0 | 0 |
| Change in Working Capital | 2.5M | (943.05K) | (1.16M) |
| Accounts Receivables | (154.02K) | (164.98K) | (44.29K) |
| Inventory | (55.87K) | 38.18K | 1.35K |
| Accounts Payables | 180.4K | 210.28K | (204.69K) |
| Other Working Capital | 2.53M | (1.03M) | (913.02K) |
| Other Non-Cash Items | 60.9K | (37.45K) | (10.89K) |
| Operating Cash Flow | 2.43M | 295.43K | 425.89K |
| Capital Expenditures | (606.19K) | (210.6K) | (287.53K) |
| Acquisitions (Net) | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | (1.94M) |
| Sales of Investments | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 |
| Investing Cash Flow | (606.19K) | (210.6K) | (2.23M) |
| Debt Repayment | (177.92K) | (115.85K) | 48.93K |
| Common Stock Issued | 0 | 0 | 0 |
| Common Stock Repurchased | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 |
| Other Financing Activities | (1.25M) | 216K | 472.37K |
| Financing Cash Flow | (1.43M) | 100.15K | 521.3K |
| Effect of Forex Changes | 5.66K | (10.51K) | (4.62K) |
| Net Change in Cash | 402.99K | 174.46K | (1.29M) |
| Free Cash Flow | 1.83M | 84.83K | 138.36K |
Charming Medical Limited Class A Ordinary Shares
NASDAQ:MCTA
Intrinsic Alpha fair value
Locked
Current Price
$29.36
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.